Thermo Fisher Scientific (TMO +3.2%) moves up on upgrade to Overweight on valuation at JPMorgan....
Friday, February 1, 11:46 AM ETThermo Fisher Scientific (TMO +3.2%) moves up on upgrade to Overweight on valuation at JPMorgan. The firm says TMO's risk/reward profile has shown significant improvement, and based on comments from its call yesterday it expects the analytical equipment maker should beat current quarter guidance. The firm raises its price target to $80 from $70. View a transcript of the earnings call here: Earnings Call Transcript.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles